Published in Nature Nanotechnology on March 18, 2026, the preclinical study used mouse models and cancer cell lines, and notes a related patent application filed by the lead researchers.

The pLNP platform zips together an IDO inhibitor with IL-12–encoding mRNA, reinvigorating exhausted T cells to attack solid tumors.

Researchers are pursuing patent applications and planning long-term studies to assess safety, dosing, and efficacy across cancer types as work advances toward clinical development.

The approach is designed for broad applicability to solid tumors and is being refined to expand immune signals beyond IL-12, with ongoing work to improve systemic tumor targeting and pave the way for clinical translation.

Specifically, intratumoral pLNP treatment in colon cancer models arrested or nearly eliminated tumors within about a month and protected against recurrence, with systemic immune activation observed.

The prodrug lipid nanoparticle (pLNP) platform delivers mRNA to boost immune activation and tethers an IDO inhibitor to the ionizable lipid, creating a unified therapy that both stimulates IL-12 production and blocks tumor-induced immune suppression.

Delivering the two therapeutic functions in a single particle proved more effective than mixing them separately, underscoring the value of the dual-function design.

The study was conducted at the University of Pennsylvania with support from multiple grants and fellowships from institutions including the Burroughs Wellcome Fund, NSF, ACS, and NIH, involving a broad team of collaborators.

In preclinical models, intratumoral delivery yielded strong anti-tumor effects with minimal toxicity, while intravenous delivery produced tumor suppression with some inflammatory and liver stress markers, highlighting the need to optimize systemic delivery.

The therapy showed systemic immune effects beyond the treated tumor, including regression of distant tumors and evidence of durable immune memory that reduced recurrence in colon cancer models.

The research represents a potentially universal immunotherapy strategy for solid tumors, addressing tumor heterogeneity and immune evasion without requiring tumor-marker identification.

Delivery route matters: intratumoral administration shows strong efficacy with minimal toxicity, whereas intravenous delivery yields systemic immune effects but with inflammatory side effects, guiding future optimization for safety and targeting.